Convalescent plasma as a potential therapy for COVID-19
Top Cited Papers
Open Access
- 27 February 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 20 (4), 398-400
- https://doi.org/10.1016/s1473-3099(20)30141-9
Abstract
No abstract availableFunding Information
- Chongqing Medical University (YBXM-2019-013)
This publication has 13 references indexed in Scilit:
- First Case of 2019 Novel Coronavirus in the United StatesNew England Journal of Medicine, 2020
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injuryThe Lancet, 2020
- Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivoScience, 2016
- HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1Science, 2016
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysisThe Journal of Infectious Diseases, 2014
- Hyperimmune IV Immunoglobulin TreatmentChest, 2013
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011
- Treatment of severe acute respiratory syndromeEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patientsClinical Microbiology & Infection, 2004